IL2 and intervertebral disk degenerative disorder: The partial recovery of miR-186-5p expression during mid-stage disease, coinciding with peak IL-2 levels, may represent a potential therapeutic window in which restoring miR-186-5p could mitigate inflammation and slow disc degeneration.